TransCode Therapeutics (NASDAQ: RNAZ) announced positive Phase 1a clinical data for its lead candidate TTX-MC138 at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. The results, presented in poster 1025P, showed that the therapy met its primary safety endpoint with no dose-limiting toxicities across four dose levels ranging from 0.8 mg/kg to 4.8 mg/kg, administered every 28 days. The trial also demonstrated dose-dependent plasma exposure, confirming that the drug reaches targeted exposure levels in patients with previously treated advanced solid tumors.
The safety profile is a crucial milestone for TransCode, as early-stage toxicity is a leading cause of failure for novel cancer therapies. The absence of dose-limiting toxicities supports the continued evaluation of TTX-MC138 and reduces regulatory risk as the company moves toward later-stage trials. The full press release is available at https://ibn.fm/g3E2F.
Beyond safety, the study reported disease stabilization and extended progression-free intervals in a subset of patients. While the trial is not designed to measure efficacy, these observations provide early signals of antitumor activity and support the biologic rationale for targeting microRNA-10b, a biomarker of metastasis. If confirmed in larger studies, TTX-MC138 could offer a new approach for metastatic tumors that overexpress microRNA-10b, addressing a significant unmet need in oncology.
The Phase 1a trial is an ongoing multicenter, open-label study evaluating safety, tolerability, pharmacokinetics, antitumor activity, and exploratory biomarkers. The dose-dependent exposure data are particularly encouraging because they suggest the therapy can be reliably delivered at therapeutic levels without unexpected toxicity. This pharmacokinetic consistency is essential for designing subsequent trials and for potential combination strategies with other agents.
TransCode Therapeutics is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. The company’s pipeline includes additional first-in-class candidates designed to mobilize the immune system against cancer cells. For investors, the latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ.
The announcement was distributed through InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio at IBN. InvestorWire provides wire-grade press release syndication, including editorial syndication to 5,000+ outlets and social media distribution to millions of followers, helping companies like TransCode reach a broad investor audience. For full terms and disclaimers, visit https://www.InvestorWire.com/Disclaimer.
